Evidence map›Paper›PMID 23287772›Full record

ArticleJournal of radiation research2013

Efficacy of FDG-PET for defining gross tumor volume of head and neck cancer.

Chikae Kajitani, Isao Asakawa, Fumiaki Uto, Emiko Katayama, Kazuya Inoue, Tetsuro Tamamoto, Norihisa Shirone, Hideyuki Okamoto, Tadaaki Kirita, Masatoshi Hasegawa

Abstract read
In one paragraph

Article in Journal of radiation research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chikae KajitaniDepartment of Radiation Oncology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Japan.
Isao Asakawa
Fumiaki Uto
Emiko Katayama
Kazuya Inoue
Tetsuro Tamamoto
Norihisa Shirone
Hideyuki Okamoto
Tadaaki Kirita
Masatoshi Hasegawa

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We analyzed the data for 53 patients with histologically proven primary squamous cell carcinoma of the head and neck treated with radiotherapy between February 2006 and August 2009. All patients underwent contrast-enhanced (CE)-CT and (18)F-fluorodeoxyglucose (FDG)-PET before radiation therapy planning (RTP) to define the gross tumor volume (GTV). The PET-based GTV (PET-GTV) for RTP was defined using both CE-CT images and FDG-PET images. The CE-CT tumor volume corresponding to a FDG-PET image was regarded as the PET-GTV. The CE-CT-based GTV (CT-GTV) for RTP was defined using CE-CT images alone. Additionally, CT-GTV delineation and PET-GTV delineation were performed by four radiation oncologists independently in 19 cases. All four oncologists did both methods. Of these, PET-GTV delineation was successfully performed in all 19 cases, but CT-GTV delineation was not performed in 4 cases. In the other 15 cases, the mean CT-GTV was larger than the PET-GTV in 10 cases, and the standard deviation of the CT-GTV was larger than that of the PET-GTV in 10 cases. Sensitivity of PET-GTV for identifying the primary tumor was 96%, but that of CT-GTV was 81% (P < 0.01). In patients with oropharyngeal cancer and tongue cancer, the sensitivity of CT-GTV was 63% and 71%, respectively. When both the primary lesions and the lymph nodes were evaluated for RTP, PET-GTV differed from CT-GTV in 19 cases (36%). These results suggested that FDG-PET is effective for defining GTV in RTP for squamous cell carcinoma of the head and neck, and PET-GTV evaluated by both CE-CT and FDG-PET images is preferable to CT-GTV by CE-CT alone.

Indexed as

Fluorodeoxyglucose F18Positron-Emission TomographyRadiopharmaceuticalsTomography, X-Ray ComputedCarcinoma, Squamous CellComputer SimulationContrast MediaFemaleHead and Neck NeoplasmsHumansImaging, Three-DimensionalMaleObserver VariationReproducibility of ResultsSensitivity and SpecificityContrast MediaFluorodeoxyglucose F18RadiopharmaceuticalsFDG-PETgross tumor volumehead and neck cancertarget delineation

Identifiers

PMID23287772
PMCPMC3709660

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.